Salwan Al Mutar named director of clinical research at START Dallas-Fort Worth

What NHS-Galleri taught us—and what it didn’t

On May 30, GRAIL reported the full results of the NHS-Galleri trial in an oral presentation at the ASCO Annual Meeting.

June 18, 2026

The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies

The NHS-Galleri trial presented at ASCO was the largest, prospective, randomized trial of a multicancer early detection test (MCED) to date. The study enrolled approximately 143,000 asymptomatic adults (ages 50-77) and was the first of its kind to assess clinical utility of an MCED test for cancer screening.

June 18, 2026

Vol.52 No.24

By Bryan Bassig, Catherine R. Marinac, David M. Routman, Elizabeth K. O'Donnell, Jennifer Keating Litton, Karthik V. Giridhar, Kennedy Ng Yao Yi, Kurt Giles, Nima Nabavizadeh, Ora K. Gordon, Rebecca Kaltman and Shawn Kothari

Cancer Policy

OMB proposed rule could end 50% of currently active clinical trials, Stand up for Science analysis finds

An analysis by Stand up for Science found that the White House Office of Management and Budget’s recently proposed rule, “Regulation for Federal Financial Assistance,” if finalized, could result in termination of nearly 50% of active clinical research studies.

Ian Krop named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs at Yale

Ian E. Krop was named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs for Yale Cancer Center and Smilow Cancer Hospital.

June 18, 2026

Vol.52 No.24

Clinical Roundup

All-oral regimen of decitabine-cedazuridine + venetoclax yields 47% complete response rate, ASCERTAIN-V phase I/II clinical trial finds

The ASCERTAIN-V phase I/II clinical trial, which evaluated the first all-oral regimen of decitabine-cedazuridine plus venetoclax in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive induction chemotherapy, demonstrated favorable response rates and survival with expected myelosuppressive effects.

June 18, 2026

Vol.52 No.24

Clinical Roundup

Talvey + Darzalez Faspro shows significant survival gains in r/r MM, phase III MonumenTAL-3 study finds

Talvey (talquetamab-tgvs), a GPRC5D bispecific antibody, in combination with Darzalez Faspro (daratumumab and hyaluronidase-fihj) with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72% and clinically meaningful reduction of up to 53% in the risk of death compared to the standard regimen of Darzalez Faspro, pomalidomide, and dexamethasone in patients with relapsed/refractory multiple myeloma, according to the results of the investigational phase III MonumenTAL-3 study.

June 18, 2026

Vol.52 No.24

Salwan Al Mutar named director of clinical research at START Dallas-Fort Worth

YOU MAY BE INTERESTED IN

What NHS-Galleri taught us—and what it didn’t

The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies

OMB proposed rule could end 50% of currently active clinical trials, Stand up for Science analysis finds

Ian Krop named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs at Yale

All-oral regimen of decitabine-cedazuridine + venetoclax yields 47% complete response rate, ASCERTAIN-V phase I/II clinical trial finds

Talvey + Darzalez Faspro shows significant survival gains in r/r MM, phase III MonumenTAL-3 study finds

Renew today!

Subscriber content

Never miss an issue!

Login